预约演示
更新于：2025-05-24
Sulpiride
舒必利
更新于：2025-05-24
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H23N3O4S |
InChIKeyBGRJTUBHPOOWDU-UHFFFAOYSA-N |
CAS号15676-16-1 |
关联
18
项与 舒必利 相关的临床试验CTR20242937
舒必利片在健康受试者中的随机、开放、单剂量、双周期、自身交叉、空腹及餐
后状态下生物等效性试验
NCT05208294
The Role of Dopamine, Reward Learning and Prefrontal Activity in Expectation-induced Mood Enhancement
NCT05884671
Dopaminergic Mechanisms of Gating Working Memory, Learning and Motivation: a Pharmaco-fMRI Study
100 项与 舒必利 相关的临床结果
登录后查看更多信息
100 项与 舒必利 相关的转化医学
登录后查看更多信息
100 项与 舒必利 相关的专利（医药）
登录后查看更多信息
7,073
项与 舒必利 相关的文献（医药）2025-08-01NEUROPHARMACOLOGY
Aripiprazole: The antiallodynic and antihyperalgesic effects in chronic constriction injury-induced neuropathic pain and reserpine-induced fibromyalgia with possible mechanisms
Article
作者: Arslan, Rana ; Aykaç, Özlem ; Bektas, Nurcan ; Okcay, Yagmur
Neuropathic pain, caused by peripheral or central nerve damage, and fibromyalgia, a chronic musculoskeletal disorder, require complex treatment approaches. This study evaluated the antiallodynic and antihyperalgesic effects of aripiprazole (1, 5, and 10 mg/kg, i. p.) in rats with chronic constriction injury-induced neuropathic pain and reserpine-induced fibromyalgia in female Sprague-Dawley rats, using electronic von Frey and Hargreaves tests. Dopaminergic, serotonergic, and opioidergic systems' roles were assessed through pre-treatment with sulpiride (50 mg/kg), WAY 100635 (1 mg/kg), and naloxone (1 mg/kg), respectively. The effect of aripiprazole was compared with 30 mg/kg pregabalin in the neuropathic pain model and 30 mg/kg duloxetine in the fibromyalgia model. Aripiprazole demonstrated significant antiallodynic and antihyperalgesic activity in both models. It did not change locomotor activity at a dose of 1 mg/kg but caused a decrease at a dose of 5 mg/kg. Dopamine D2, serotonin 5-HT1A, and opioidergic receptors contributed to aripiprazole's effects at varying levels. This study highlights the potential use of aripiprazole for managing neuropathic pain and fibromyalgia by targeting multiple receptor systems. The findings demonstrate the potential use of aripiprazole alone or as an adjuvant in the treatments of neuropathic pain and fibromyalgia.
2025-07-01BEHAVIOURAL BRAIN RESEARCH
Interaction of opioid and D2-like dopamine receptors in the nucleus accumbens modulate acute pain-related behaviors
Article
作者: Seddighfar, Masoud ; Haghparast, Abbas ; Vazifeshenas, Ali
As a pivotal component of the reward circuitry in the brain, the nucleus accumbens (NAc) is essential in influencing pain-related reactions. Its involvement suggests a significant interplay with the systems that utilize opioids and dopamine. This research investigated the interplay between opioidergic and D2-like dopamine receptors within the NAc on acute pain-related behaviors. Male Wistar rats underwent unilateral cannula implantation into the NAc. In the initial phase, separate groups of animals were administered varying doses of morphine (5, 10, and 25 mmol/0.5 μL) and quinpirole (2, 4, 8, and 16 mmol/0.5 μL), acting as an opioid and a D2-like receptor agonist in the NAc, respectively. Following this, the animals received different doses of sulpiride (1.5, 3, 6, 12, and 24 mmol/0.5 μl), a D2-like receptor antagonist, prior to receiving an effective dose of morphine (10 mmol/0.5 μL). In the final phase, animals were given varying doses of naloxone (1.5, 5, 15, and 45 mmol/0.5 μl) before administering the efficacious dose of quinpirole (8 mmol/0.5 μl). This study employed the tail-flick test, which was subsequently used to assess the subjects' acute pain threshold. The primary results indicated that the administration of morphine and quinpirole into the NAc independently produced antinociceptive effects. Conversely, injecting sulpiride into the NAc significantly reduced the pain-relieving effects of morphine in the NAc. Additionally, introducing naloxone into the NAc greatly weakened the antinociceptive consequences linked to the quinpirole administration. The findings suggest a possible interaction between the dopamine and opioid systems within the NAc that may lead to pain relief. This understanding could guide the creation of new medications designed to enhance pain management while reducing the risks linked to conventional opioid treatments.
2025-06-01BEHAVIOURAL BRAIN RESEARCH
Contribution of D1- and D2-like dopamine receptors in the ventral tegmental area to the stress-induced analgesia in the animal model of acute pain
Article
作者: Ghalandari-Shamami, Mohadeseh ; Haghparast, Abbas ; Danesh, Elaheh ; Saghafi, Mohammad ; Mousavi, Zahra
Stressful situations have been observed to enhance pain thresholds, a phenomenon recognized as stress-induced analgesia (SIA). The mechanism underlying SIA involves a combination of endogenous opioids and catecholamines like dopamine. Dopamine in the ventral tegmental area (VTA) is implicated in nociceptive responses. The present study aims to examine the distinct contributions of D1- and D2-like dopamine receptors within the VTA in modulating the impact of exposure to restraint stress (RS) on nociceptive thresholds during the tail-flick test. One hundred five adults male Wistar rats underwent stereotaxic surgery, wherein cannulas were unilaterally implanted into the VTA. Following a recovery period, animals in separate groups received different doses of SCH-23390 or Sulpiride as D1- and D2-like receptor antagonists, respectively, or their corresponding vehicles 5 min before exposure to RS (3 h per rat). Subsequently, a pain threshold assessment was conducted over one hour using a tail-flick apparatus. The obtained findings indicate that exposure to RS, as a form of psychological stress, considerably enhanced antinociceptive behavior in the acute pain model. The reduction of this response was effectively observed through the blockade of dopamine receptors in the VTA, with equal potency attributed to the D2- and D1 like dopamine receptor antagonist. These outcomes provide insights into the potential involvement of the dopaminergic system in pain control under stressful conditions, offering a promising future for developing pharmacological agents and psychological methodologies for pain management.
100 项与 舒必利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1979-08-03 | |
| 精神分裂症 | 日本 | 1979-08-03 | |
| 十二指肠溃疡 | 日本 | 1973-01-13 | |
| 胃溃疡 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性视网膜病变 | 临床前 | 墨西哥 | 2020-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Sulpiride-treated group | 膚齋築築積齋艱簾簾顧(範鬱鏇鹽顧齋鑰壓顧廠) = 醖鏇醖鹹網壓鏇鹹顧願 遞鬱顧繭願憲蓋觸鹹獵 (鬱鏇鏇簾鬱窪鹽遞鑰獵 ) | - | 2020-09-12 | ||
膚齋築築積齋艱簾簾顧(範鬱鏇鹽顧齋鑰壓顧廠) = 鏇願顧醖廠構糧選願觸 遞鬱顧繭願憲蓋觸鹹獵 (鬱鏇鏇簾鬱窪鹽遞鑰獵 ) | |||||||
N/A | 糖尿病性视网膜病变 prolactin | - | 顧積鏇範築構壓窪網衊(鏇鏇觸蓋夢衊鑰築淵願) = reduced diabetes-induced retinal vasopermeability 獵廠鏇夢憲醖醖壓鏇蓋 (衊觸憲繭廠範鑰築鬱遞 ) | - | 2020-06-01 | ||
(Control (non-diabetic)) | |||||||
N/A | - | 膚構積觸鹹鏇範壓鹽構(鑰膚範鹽鏇遞積遞願鏇) = 鏇選鬱鏇艱鹹衊獵糧鹽 齋願遞簾鏇積鏇顧壓鹹 (顧廠簾簾窪襯鑰網壓獵 ) | - | 2018-10-01 | |||
Flupenthixol melitracen | 膚構積觸鹹鏇範壓鹽構(鑰膚範鹽鏇遞積遞願鏇) = 餘鏇簾網觸糧範築積鹽 齋願遞簾鏇積鏇顧壓鹹 (顧廠簾簾窪襯鑰網壓獵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用